SCHEMBL5374711

SCHEMBL5374711

Cn1ccc2c(N3CCNCC3)cccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.56
HTR5A P47898 2/20 0.54
HTR3E A5X5Y0 1/20 0.54
HTR3B O95264 1/20 0.54
CYP1A2 P05177 1/20 0.54
HTR1A P08908 1/20 0.54
CYP2D6 P10635 1/20 0.54
NCF1 P14598 1/20 0.54
TSHR P16473 1/20 0.54
NFKB1 P19838 1/20 0.54
HTR1D P28221 1/20 0.54
HTR1B P28222 1/20 0.54
HTR2A P28223 1/20 0.54
HTR7 P34969 1/20 0.54
MTOR P42345 1/20 0.54
HTR3A P46098 1/20 0.54
HTR3D Q70Z44 1/20 0.54
HTR3C Q8WXA8 1/20 0.54
HSD17B10 Q99714 1/20 0.54
SIGMAR1 Q99720 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30610357 1.00 HTR6 (0.56) HTR6HTR5AHTR3EHTR3BCYP1A2
SCHEMBL3596171 0.83 DRD2 (0.58) HTR6HTR3EHTR3BHTR1ATSHR
SCHEMBL17889356 0.81 HTR2C (0.40) HTR6HTR5AHTR3EHTR3BCYP1A2
SCHEMBL18029065 0.81 ATR (0.46) HTR6CYP1A2HTR1ANCF1HTR2A
SCHEMBL13798789 0.81 HTR6 (0.56) HTR6HTR5AHTR3EHTR3BCYP1A2
SCHEMBL6625130 0.80 HTR6 (0.52) HTR6HTR5AHTR3EHTR3BCYP1A2
SCHEMBL6193597 0.80 HTR6 (0.62) HTR6HTR5AHTR3EHTR3BCYP1A2
SCHEMBL6191880 0.80 HTR6 (0.52) HTR6HTR5AHTR3EHTR3BCYP1A2
SCHEMBL6191957 0.78 HTR6 (0.53) HTR6HTR5AHTR3EHTR3BCYP1A2
SCHEMBL13790208 0.78 HTR6 (0.39) HTR6CYP1A2HTR1ATSHRHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3575294-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Les Laboratoires Servier (FR) 2019-12-04 EP disclosed
EP-3237406-B1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS GALAPAGOS NV (BE) 2019-02-06 EP disclosed
US-7557098-B2 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-07-07 US disclosed
US-7541370-B2 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-02 US disclosed
US-20080200455-A1 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands WYETH (US) 2008-08-21 US disclosed
US-20080064684-A1 Sub-type selective serotonin receptor agonists; antidepressants; schizophrenia, Alzheimer's Disease, Parkinson's Disease; alkylation or amidation of the heterocyclylbenzazole with an alkylhalide or acylhalide WYETH (US) 2008-03-13 US disclosed
US-7282495-B2 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-10-16 US disclosed
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 HTR6 789/4885HTR5A 376/4885HTR3E 1510/4885
US-20080064684-A1 Sub-type selective serotonin receptor agonists; antidepressants; schizophrenia, Alzheimer's Disease, Parkinson's Disease; alkylation or amidation of the heterocyclylbenzazole with an alkylhalide or acylhalide HTR6, HTR3B, HTR2B HTR6 1/4885HTR5A 12/4885HTR3E 20/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 HTR6 789/4885HTR5A 376/4885HTR3E 1510/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 HTR6 789/4885HTR5A 376/4885HTR3E 1510/4885
US-20080200455-A1 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands HTR6, HTR1B, HTR1A HTR6 1/4885HTR5A 5/4885HTR3E 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.